• ABOUT HALIX
    • Our company
    • Our facility
    • Our approach
    • News and events
  • HALiXPEDITE PLATFORM
  • DEVELOPMENT & MANUFACTURING
    • GMP Manufacturing
      • Virus manufacturing
      • Protein manufacturing
      • Fill and finish and lyophilization
    • Development
  • CAREERS
  • CONTACT

HALiXPEDITE: Transforming Biologics Therapy Development Programs with Seamless R&D to GMP Integration

HALIX is featured in Business Focus Magazine

Rocketvax and HALIX Collaborate to Advance the VIRUFLEX Platform and Next-Generation Nasal COVID-19 Vaccine_CDMO_vaccine

Rocketvax and HALIX Collaborate to Advance the VIRUFLEX Platform and Next-Generation Nasal COVID-19 Vaccine

HALIX Appoints Dr. Lutz Hilbrich as New Chief Executive Officer

HALIX Part of Leading Innovator Consortium for 2024 MacRobert Award

Richard van Rijnsoemer, HALIX, CDMO, Business Development

HALIX Appoints Richard van Rijnsoever as Vice President of Business Development and Project Management

Alex Huybens appointed as Chief Executive Officer (CEO) of HAL Allergy Holding B.V. and HALIX B.V.

Update On HALIX’s Commercial Manufacture Of COVID-19 Vaccine

HALIX facility approved for AstraZeneca’s COVID-19 vaccine active substance manufacturing

HALIX’s Agreement With AstraZeneca For Commercial Manufacture Of COVID-19 Vaccine

1 2 Next

Get in touch with us directly

André Habel, Ph.D.
Senior Director Business Development  | Viral vectors and vaccines
Mobile: +31 (0) 61 5425 448

Djamel Deken, M.Sc.
Senior Director Business Development | Recombinant proteins and antibodies
Mobile: +31 (0) 62 7193 828

Bardia Rofouie, DVM, MBA
Director Business Development | Fill finish and lyophilization
Mobile: +31 (0) 62 1888 376